Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1830965 | 0.92 | MET (0.51) | METPIK3CADYRK1APDPK1PIK3CG | |
| SCHEMBL2530711 | 0.89 | MET (0.61) | METPIK3CA | |
| SCHEMBL1840243 | 0.85 | MET (0.50) | METPIK3CAPIK3CGCYP3A4MTOR | |
| SCHEMBL2529642 | 0.81 | MET (0.54) | METPIK3CACYP3A4 | |
| SCHEMBL1830028 | 0.81 | MET (0.54) | METPIK3CAPIK3CGCYP3A4MTOR | |
| SCHEMBL1841045 | 0.81 | MET (0.66) | METCYP3A4 | |
| SCHEMBL2536920 | 0.81 | ABL1 (0.52) | MET | |
| SCHEMBL2530332 | 0.81 | TGFBR1 (0.42) | CYP3A4 | |
| SCHEMBL1831604 | 0.80 | MET (0.38) | METPIK3CA | |
| SCHEMBL2534423 | 0.79 | MET (0.49) | METDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257171-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | claimed |
| US-20110257171-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257171-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS | MET, ALK, RET | MET 1/4885PIK3CA 1202/4885DYRK1A 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.